← All companies
$1,443.50
+1.14% (+$16.22) on the day
Close Nov 13, 2026
Market cap
$1.36T
1 month
+15.33%
52-week range
$850.51–$1,460.00
Last month
Why we cover it
Made Big Pharma's first psychedelic buyout: it acquired AtaiBeckley, which closed September 11, 2026, for up to $3.8 billion including a later milestone payment. The deal brought in a nasal 5-MeO-DMT drug for depression.
Financials
| Cash & equivalents | $4.88B | as of Sep 30, 2026 · 10-Q |
| Revenue | $24.4B | quarter ended Sep 30, 2026 · 10-Q |
| Research & development | $4.25B | quarter ended Sep 30, 2026 · 10-Q |
| Net income (loss) | $6.45B | quarter ended Sep 30, 2026 · 10-Q |
From the company's SEC filings. See all filings ↗
Clinical trials Trials tracker
| Trial | Compound | Stage |
|---|---|---|
| DMX-1002 (Ibogaine HCl) for Opioid Use Disorder | Ibogaine | Phase 1 complete (2023); Phase 2a not advanced |
| BPL-003 for Treatment-Resistant Depression | 5-MeO-DMT | Phase 3 (ReConnection, ongoing) |
Patents Patent tracker
| Holder | Compounds | Granted | Pending | Expire |
|---|---|---|---|---|
| Beckley Psytech Limited | 5-MeO-DMT, DMT | 8 | 8 | 2042–2044 |
| Atai Therapeutics, Inc. | Psilocybin, Ibogaine, DMT, 5-MeO-DMT | 3 | 6 | 2042–2043 |
News (5)
- Oct 28, 2026 Eli Lilly's Carole Ho Says 5-MeO-DMT "Fits the Spravato Model" as Investors Call Pharma "Cash Rich and Pipeline Poor"
- Sep 28, 2026 A Second Dose of AtaiBeckley's 5-MeO-DMT Drug Also Beat Depression, Trial Data Shows
- Sep 9, 2026 Eli Lilly Is Buying AtaiBeckley for Up to $3.8 Billion — Big Pharma's First Psychedelic Buyout
- Aug 24, 2026 New on Altitude: The 5-MeO-DMT Patent Race Has a Twist
- May 20, 2025 Synthetic 5-MeO-DMT Showed a 55% Response Rate — Even Alongside an SSRI
In the Journal (14)
- Nov 11, 2026 Altitude People Series, Week 3 — Business: The Billionaire Who Built a Psychedelics Company on One Mushroom Trip
- Nov 9, 2026 The Day After Approval: Which States Will Let Doctors Prescribe Psilocybin
- Oct 20, 2026 Altitude People Series, Week 1 — Sports: The Athletes Who Went Public About Psychedelics, and Why
- Oct 20, 2026 MK-Ultra, Explained: What the CIA Actually Did With "Brainwashing Drugs" — and Why Congress Is Still Asking About It
- Sep 29, 2026 Only 3 of 10 Psychedelic Companies Lobby Washington. One Just Joined — Twice, in the Same Quarter.
- Sep 23, 2026 Which Psychedelic-Company CEO's Pay Actually Matched Their Stock's Performance? We Checked All 10 — Almost None Did.
- Sep 21, 2026 19% of American Adults Have Anxiety. Every Drug Treating It Is a Decades-Old Generic — Here's Who Wins If DT120 Changes That
- Sep 17, 2026 The Psychedelic Money Graveyard: Renames, Reverse Mergers, and the Companies That Didn't Make It
- Sep 11, 2026 The Psychedelic Money Rankings: $11 Billion Public, $1.6 Billion Private, $140 Million From Governments
- Aug 31, 2026 Ibogaine's Flagship Drug Hit a Cardiac Signal and a Lawsuit. A Different Drug Is Now Leading.
- Aug 24, 2026 The 5-MeO-DMT Patent Race Has a Twist: The Clinical Leader Barely Owns Any of It
- Aug 17, 2026 677 Patents and One FDA Rejection: Mapping the Psychedelic Drug Pipeline
Prices are end-of-day closes from Nasdaq; financials come from SEC filings. Not investment advice.